Skip to search formSkip to main content

BIIL 284

Known as: BIIL 284 BS, BIIL-284, BIIL-284 BS 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND A clinical study to investigate the leukotriene B(4) (LTB(4))-receptor antagonist BIIL 284 in cystic fibrosis (CF… Expand
Is this relevant?
2013
2013
Insufficient oxygen delivery to organs leads to tissue dysfunction and cell death. Reperfusion, although vital to organ survival… Expand
  • figure 3
Is this relevant?
2007
2007
BACKGROUND Several clinical and experimental lines of evidence suggest that leucotriene B4 (LTB4), an arachidonic acid derivative… Expand
  • figure 1
  • table 1
  • table 2
Is this relevant?
2007
2007
  • Nature Clinical Practice Rheumatology
  • 2007
A multicenter, randomized, double-blind trial has failed to demonstrate efficacy of BIIL 284— a leukotriene B4 (LTB4) receptor… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Leukotriene B(4) (LTB(4)), a potent leukocyte chemoattractant derived from the 5-lipoxygenase metabolism of arachidonic acid… Expand
Is this relevant?
2004
2004
BACKGROUND Leukotriene B4 (LTB(4)) has a key role in the pathophysiology of rheumatoid arthritis (RA). OBJECTIVE To investigate… Expand
Is this relevant?
2003
2003
Background: Leukotriene B4 (LTB4) has a key role in the pathophysiology of rheumatoid arthritis (RA). Objective: To investigate… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2001
2001
BIIL 284 is a new LTB(4) receptor antagonist. It is a prodrug and has negligible binding to the LTB(4) receptor. However… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?